In vitro and in vivo studies revealed that G9a represses a gene signature highly associated with mutant KRAS-regulating and ECM-regulating genes, including Mmp10, which partially mediates the tumorigenicity of G9a-depleted tumor cells. The gene discussed is MMP10; the disease is neoplasm.